American journal of obstetrics and gynecology
-
Am. J. Obstet. Gynecol. · Jun 2017
17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study.
17-alpha Hydroxyprogesterone caproate for prevention of recurrent preterm birth is recommended for use in the United States. ⋯ 17-alpha Hydroxyprogesterone caproate was ineffective for prevention of recurrent preterm birth and was associated with an increased rate of gestational diabetes.
-
Am. J. Obstet. Gynecol. · Jun 2017
Two-year continuation of intrauterine devices and contraceptive implants in a mixed-payer setting: a retrospective review.
As the popularity of long-acting reversible contraception increases, so does the need for accurate data on method continuation in diverse clinical settings. We determined 2-year continuation rates for the levonorgestrel 52-mg intrauterine device, the copper T380A intrauterine device, and the 68-mg etonogestrel contraceptive implant in an academic healthcare system with mixed-payer reimbursement. ⋯ Three-quarters of women with an intrauterine device or implant continue using it for 2 years. In this cohort, the 2-year continuation rates were 77.8%, 73.1%, and 75.9% for the levonorgestrel 52-mg intrauterine device, copper T380A intrauterine device, and 68-mg etonogestrel implant, respectively.